MX2023002837A - Uso de cannabidivarina en el tratamiento de crisis convulsivas asociadas a sindromes de epilepsia raros relacionados con anomalias geneticas. - Google Patents
Uso de cannabidivarina en el tratamiento de crisis convulsivas asociadas a sindromes de epilepsia raros relacionados con anomalias geneticas.Info
- Publication number
- MX2023002837A MX2023002837A MX2023002837A MX2023002837A MX2023002837A MX 2023002837 A MX2023002837 A MX 2023002837A MX 2023002837 A MX2023002837 A MX 2023002837A MX 2023002837 A MX2023002837 A MX 2023002837A MX 2023002837 A MX2023002837 A MX 2023002837A
- Authority
- MX
- Mexico
- Prior art keywords
- seizures
- cannabidivarin
- treatment
- epilepsy syndromes
- motor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2014250.1A GB202014250D0 (en) | 2020-09-10 | 2020-09-10 | Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| PCT/EP2021/074661 WO2022053486A1 (en) | 2020-09-10 | 2021-09-08 | Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002837A true MX2023002837A (es) | 2023-03-17 |
Family
ID=73149611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002837A MX2023002837A (es) | 2020-09-10 | 2021-09-08 | Uso de cannabidivarina en el tratamiento de crisis convulsivas asociadas a sindromes de epilepsia raros relacionados con anomalias geneticas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230346809A1 (enExample) |
| EP (1) | EP4210685B1 (enExample) |
| JP (1) | JP7817990B2 (enExample) |
| KR (1) | KR20230066417A (enExample) |
| CN (1) | CN116234580A (enExample) |
| AU (1) | AU2021341452A1 (enExample) |
| CA (1) | CA3191266A1 (enExample) |
| GB (2) | GB202014250D0 (enExample) |
| MX (1) | MX2023002837A (enExample) |
| WO (1) | WO2022053486A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB202009321D0 (en) | 2020-06-18 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| CA3264785A1 (en) | 2022-08-12 | 2024-02-15 | Jazz Pharmaceuticals Research Uk Limited | ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487183B (en) * | 2011-01-04 | 2018-10-03 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| TWI583374B (zh) * | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2495118B (en) * | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2549278B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| GB2569961B (en) * | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB2588458A (en) * | 2019-10-25 | 2021-04-28 | Gw Res Ltd | Cannabidivarin preparations |
-
2020
- 2020-09-10 GB GBGB2014250.1A patent/GB202014250D0/en not_active Ceased
-
2021
- 2021-09-01 GB GB2112440.9A patent/GB2599492A/en not_active Withdrawn
- 2021-09-08 CN CN202180062304.9A patent/CN116234580A/zh active Pending
- 2021-09-08 WO PCT/EP2021/074661 patent/WO2022053486A1/en not_active Ceased
- 2021-09-08 US US18/044,941 patent/US20230346809A1/en active Pending
- 2021-09-08 CA CA3191266A patent/CA3191266A1/en active Pending
- 2021-09-08 MX MX2023002837A patent/MX2023002837A/es unknown
- 2021-09-08 KR KR1020237012089A patent/KR20230066417A/ko active Pending
- 2021-09-08 EP EP21769152.6A patent/EP4210685B1/en active Active
- 2021-09-08 JP JP2023515815A patent/JP7817990B2/ja active Active
- 2021-09-08 AU AU2021341452A patent/AU2021341452A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023540614A (ja) | 2023-09-25 |
| GB202112440D0 (en) | 2021-10-13 |
| KR20230066417A (ko) | 2023-05-15 |
| JP7817990B2 (ja) | 2026-02-19 |
| AU2021341452A1 (en) | 2023-03-23 |
| CA3191266A1 (en) | 2022-03-17 |
| EP4210685B1 (en) | 2025-11-26 |
| GB2599492A (en) | 2022-04-06 |
| US20230346809A1 (en) | 2023-11-02 |
| GB202014250D0 (en) | 2020-10-28 |
| WO2022053486A1 (en) | 2022-03-17 |
| CN116234580A (zh) | 2023-06-06 |
| EP4210685A1 (en) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pegoretti et al. | Inflammation and oxidative stress in multiple sclerosis: consequences for therapy development | |
| Shi et al. | Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APP swe/PS 1dE9 transgenic mice | |
| MXPA04000222A (es) | Combinaciones para el tratamiento de desordenes inflamatorios. | |
| AU2002363250A1 (en) | Pyrazole-amides and-sulfonamides | |
| WO2019226514A3 (en) | Molecular gene signatures and methods of using same | |
| EP1506196A4 (en) | pyrazolopyrimidine | |
| WO2004009610A3 (en) | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | |
| AU2003256755A1 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
| WO2009020481A3 (en) | Therapeutic compositions and methods for treating gram-negative bacterial infections | |
| JOP20200041A1 (ar) | تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي | |
| WO2003030823A3 (en) | Combinations for the treatment of immunoinflammatory disorders | |
| ZA200604253B (en) | Methods and reagents for the treatment of inflammatory disorders | |
| WO2006002058A3 (en) | Treatment of autism | |
| Zuo | Mitochondrial imbalance in Down syndrome: A driver of accelerated brain aging? | |
| WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
| SG148186A1 (en) | Methods and reagents for the treatment of inflammatory disorders | |
| NO20054913L (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
| TW200716172A (en) | Pharmaceutical compositions for treating lower motor neuron diseases | |
| TW200511999A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
| Qian et al. | Astrocyte autophagy in neurodegenerative diseases: current progress in mechanisms and therapeutics | |
| CA3266356A1 (en) | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | |
| WO2000062795A3 (en) | UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS | |
| WO2022221574A3 (en) | Products and methods for inhibition of expression of dynamin-1 variants | |
| Dong et al. | Early intervention for psychosis with N-methyl-D-aspartate receptor modulators | |
| EP4541348A3 (en) | Magnesium-containing oxytocin formulations and methods of use |